公开(公告)号：US20150118322A1

公开(公告)日：2015-04-30

申请号：US14514137

申请日：2014-10-14

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Ya-Chin LO ,  Hsiang-Fa LIANG ,  Ming-Cheng WEI ,  Maggie J.M. LU ,  Min-Ying LIN ,  Chih-Peng LIU ,  Chun-MIN LIU ,  Hsiang-Wen TSENG ,  Tse-Min TENG ,  Jui-Hsiang CHEN ,  Yi-Man CHOU ,  Yi-Ting HSIEH ,  Chia-Mu TU

IPC: C08B37/08 ,  A61K33/24 ,  A61K31/4745 ,  A61K31/7036 ,  A61K47/48 ,  A61K31/704

CPC classification number: A61K33/24 ,  A61K31/4172 ,  A61K31/4745 ,  A61K31/555 ,  A61K31/7036 ,  A61K31/704 ,  A61K31/728 ,  A61K45/06 ,  A61K47/542 ,  A61K47/61 ,  A61K47/6921 ,  A61K2300/00

Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.

Abstract translation: 本公开提供了一种生物医学组合物，其包括：透明质酸; 修饰的组氨酸 和聚合物或C 4 -C 20烷烃，其中将经修饰的组氨酸和聚合物或C 4 -C 20烷烃接枝至透明质酸的至少一个伯羟基，以使透明质酸形成透明质酸衍生物，其中接枝率 的改性组氨酸约为1-100％，聚合物或C4-C20烷烃的接枝率约为0-40％。

公开(公告)号：US20140170250A1

公开(公告)日：2014-06-19

申请号：US14133213

申请日：2013-12-18

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： I-Horng PAN ,  Hsin-Jan YAO ,  Mei-Wei LIN ,  I-Huang LU ,  Hsin-Chieh WU ,  Hsiang-Wen TSENG ,  Ching-Huai KO ,  Chun-Chung WANG ,  Zong-Keng KUO ,  Shyh-Horng LIN ,  Yi-Cheng CHENG ,  Tien-Soung TONG

IPC: A61K36/14 ,  A61K31/357

CPC classification number: A61K31/365 ,  A61K31/7048 ,  A61K36/14 ,  A61K2300/00

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract translation: 本公开内容提供了用于抑制血管生成的药物组合物，包括有效量的桧属提取物或有效量的木酚素作为有效成分。 药物组合物还可以包括药学上可接受的载体或盐。 本公开还提供了抑制血管发生的方法，包括给予有效量的桧属提取物或有效量的木脂素作为有效成分，用于抑制有需要的受试者的血管生成。

公开(公告)号：US20160008319A1

公开(公告)日：2016-01-14

申请号：US14864203

申请日：2015-09-24

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： I-Horng PAN ,  Hsin-Jan YAO ,  Mei-Wei LIN ,  I-Huang LU ,  Hsin-Chieh WU ,  Hsiang-Wen TSENG ,  Ching-Huai KO ,  Chun-Chung WANG ,  Zong-Keng KUO ,  Shyh-Horng LIN ,  Yi-Cheng CHENG ,  Tien-Soung TONG

IPC: A61K31/365 ,  A61K31/7048

CPC classification number: A61K31/365 ,  A61K31/7048 ,  A61K36/14 ,  A61K2300/00

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract translation: 本公开提供了用于抑制血管发生的药物组合物，包括有效量的木脂素作为有效成分。 药物组合物还可以包括药学上可接受的载体或盐。 本公开还提供了一种抑制血管生成的方法，包括给予有效量的木脂素作为有效成分，用于抑制有需要的受试者的血管生成。

公开(公告)号：US20160361268A1

公开(公告)日：2016-12-15

申请号：US15142170

申请日：2016-04-29

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Chih-Peng LIU ,  Ya-Chin LO ,  Ming-Cheng WEI ,  Maggie LU ,  Shuen-Hsiang CHOU ,  Shih-Ta CHEN ,  Hsiang-Wen TSENG

IPC: A61K9/51 ,  A61K33/24 ,  A61K9/00 ,  A61K31/282

CPC classification number: A61K9/5161 ,  A61K9/0019 ,  A61K31/555 ,  A61K33/24

Abstract: Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Abstract translation: 公开了使用透明质酸纳米颗粒治疗淋巴癌的淋巴内递送方法。 这些纳米颗粒包括透明质酸衍生物和铂化合物。 透明质酸衍生物包括透明质酸，修饰的组氨酸和任选的一种或多种聚合物或C 4 -C 20烷基。 透明质酸衍生物可以包括连接聚合物或C4-C20烷基与透明质酸的连接基团。 铂化合物包括二氯（1,2-二氨基环己烷）铂（DACHPt），顺铂和奥沙利铂。 这种淋巴内递送方法在使用铂药物治疗淋巴癌方面具有显着的优势。

公开(公告)号：US20130287873A1

公开(公告)日：2013-10-31

申请号：US13871853

申请日：2013-04-26

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Pei-Yi TSAI ,  Hsiang-Wen TSENG ,  Yen-Chun CHEN ,  Hui-Chun HSU ,  Yi-Hung WEN ,  Chun-Chung WANG ,  Shu-Jiau CHIOU

IPC: A61K36/185 ,  A61K36/315

CPC classification number: A61K36/185 ,  A61K36/315

Abstract: The disclosure provides a pharmaceutical composition for promoting wound healing, including an effective amount of a Sambucus plant or an Isatis plant as an active ingredient for promoting wound healing; and a pharmaceutically acceptable carrier or medium, wherein the Sambucus plant is Sambucus formosana Nakai, and the Isatis plant is Isatis indigotica Fort.

Abstract translation: 本发明提供了一种用于促进伤口愈合的药物组合物，包括有效量的接骨木植物或靛蓝植物作为促进伤口愈合的活性成分; 和药学上可接受的载体或介质，其中所述接骨木属植物是接骨木接头甲骨虫（Nucai），靛蓝植物是靛蓝靛蓝堡（Isatis indigotica Fort）。